Maintenance therapy would be an option for some patients. Despite the significant improvements with the use of novel agents, the majority of patients eventually relapse. A number of treatment options including novel agents, which demonstrated marked clinical effects, are reported in the setting of salvage therapy. The choice of appropriate therapy for relapsed or refractory patients must take the disease status or patient status in consideration. Furthermore, a new generation of novel agents such as pomalidomide, carfilzomib or panobinostat has recently become available for relapsed or refractory myeloma. It is necessary to determine the optimal combination of drugs, administration timing and patients to be treated in future clinical trials.
Introduction
Symptomatic multiple myeloma (MM) refers to patients with MM who need systemic chemotherapy. The symptoms of MM are defined by CRAB criteria (elevated serum Calcium, Renal failure, Anemia and Bone disease) [1] . Melphalan and prednisone (MP) therapy for MM started in the 1960s and has been considered standard therapy for >40 years [2] . Several combined therapies had been developed to overcome MP and showed a superior response rate; however, they could not demonstrate prolongation of survival time [3] . Clinical trials of high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) started in the 1980s and showed better results both in response rate and relapse-free survival. HDT using highdose melphalan has been the standard therapy for younger Abstract The introduction of novel molecular targeting agents against multiple myeloma has dramatically and rapidly changed the therapeutic strategies for this incurable hematologic disease. Novel agents such as thalidomide, bortezomib and lenalidomide have significantly improved the response rate, progression-free survival, and overall survival compared with conventional chemotherapies, and made it easy to control the disease for longer periods of time. Initial therapies for newly diagnosed myeloma patients depend on the individual's clinical condition. Induction therapy with novel agents and high-dose chemotherapy followed by autologous stem cell transplantation is a standard therapy for newly diagnosed younger myeloma patients. On the other hand, several combinations of novel agents and other drugs (melphalan, prednisone, dexamethasone, etc.) are widely used as initial therapy for transplantation-ineligible myeloma patients. Although the clinical advantage of maintenance therapy after induction therapy has been reported, it is not recommend in routine practice. adult aged <65 years [4, 5] . Recently, the development of novel molecular targeting agents such as thalidomide, lenalidomide and bortezomib has demonstrated a significant survival advantage compared with conventional chemotherapies [6] [7] [8] . These new drugs may rapidly change the treatment strategies for MM requiring updates to the guidelines used in the USA, Europe and Japan [9] [10] [11] .
Patients eligible for autologous stem cell transplantation
A retrospective study of the overall survival of MM patients at the Mayo Clinic showed no significant change of median survival in patients diagnosed during 1971-2000, but a significant improvement in survival was seen during 2001-2006 [8] . This improvement in survival was predominantly among newly diagnosed younger patients treated with HDT-ASCT. In addition, a further improvement in survival was seen in patients diagnosed during 2006-2010 [12] . Importantly, the improvement was primarily seen among patients aged >65 years and was closely linked to the use of new agents in initial therapy. The survival of younger patients did not change significantly despite the use of novel agents indicating the stronger impact of HDT-ASCT on the survival of younger patients compared with novel agents. Therefore, induction therapy followed by HDT-ASCT is considered the primary therapy for newly diagnosed symptomatic patients who are aged <65 years and have no severe comorbidities.
Induction therapy and conditioning
The purpose of induction therapy is to reduce the myeloma cell burden and collect hematopoietic stem cells for ASCT. Alkylating agents such as melphalan are thought to damage the healthy hematopoietic stem cells and disturb the stem cell collection. Induction therapy for HDT-eligible patients using vincristine, adriamycin and dexamethasone (VAD) does not affect stem cell collection and induces rapid myeloma cell reduction. However, VAD has not been used for induction therapy after novel agents became clinically available. While combination therapy containing thalidomide and dexamethasone (TD) or lenalidomide and dexamethasone (LD) showed a good clinical response as induction therapy [13] [14] [15] [16] [17] , combination therapy including bortezomib and dexamethasone (BD) is widely used instead of VAD [18] [19] [20] [21] . Recently, the addition of immunomodulatory drugs (IMiDs) such as thalidomide or lenalidomide to bortezomib-based induction therapy has also been reported to be useful [22] [23] [24] [25] .
High-dose melphalan (200 mg/m 2 ) has been used as a standard conditioning regimen. Although total body irradiation (8 Gy) or bortezomib together with high-dose melphalan prior to ASCT was used to improve the clinical outcome of HDT-ASCT, it was not sufficient to replace the standard regimen of high-dose melphalan alone [26, 27] . Combinations of busulfan and melphalan or bendamustin and melphalan as conditioning regimens are now under investigation [28, 29] .
Consolidation and maintenance therapy
Consolidation therapy after ASCT including tandem ASCT has been reported. Tandem ASCT prolonged event-free survival (EFS) or overall survival (OS), especially for patients who were unable to achieve more than a very good partial response in the initial ASCT [30] [31] [32] . However, the effect of novel agents as consolidation or maintenance therapy demonstrated that a combination of bortezomib, thalidomide and dexamethasone improved the response rate at the molecular level [22, 33, 34] and that bortezomib as consolidation therapy prolonged progression-free survival (PFS) [35] .
Maintenance therapy after HDT-ASCT has been investigated in a number of trials. Six clinical trials using thalidomide as maintenance therapy showed a significant increase in PFS, and three of them also showed prolongation of OS [36] [37] [38] . Maintenance therapy with thalidomide resulted in shorter OS in patients with a high risk of cytogenetic abnormalities such as deletion of chromosome 13. Two clinical trials with lenalidomide as maintenance therapy after ASCT demonstrated the remarkable benefit of lenalidomide in PFS and one trial showed a significant increase in OS. However, the cumulative incidence of second primary malignancies (SPMs) significantly increased in patients treated with lenalidomide [39, 40] . The issue to be clarified is whether lenalidomide maintenance therapy induces an increase in SPMs and whether the benefits of lenalidomide outweigh the risk of SPMs in the maintenance setting after HDT-ASCT. A meta-analysis regarding this issue showed a 5-year cumulative risk of SPMs in the lenalidomide group of 6.9 %, which is significantly higher than the placebo group (4.8 %, p = 0.037); this increased risk was closely related to oral melphalan exposure and advanced age [41] . Because of the obvious benefits of lenalidomide, this agent should be considered for maintenance therapy.
Novel and potent agents are under development and will eventually become commercially available. These agents will result in a deeper response and improved clinical outcomes. Therefore, it is not clear whether the standard therapy for younger patients in the future is HDT-ASCT. Recently, a randomized phase 3 study was performed to confirm the role of HDT-ASCT and maintenance therapy for newly diagnosed MM patients aged <65 years. Standard high-dose melphalan followed by ASCT significantly prolonged both PFS and OS compared with MPR (melphalan, prednisone and lenalidomide) (median PFS: 43 vs 22.4 months, p < 0.001; four-year OS: 81.6 vs 65.3 %, p = 0.02). In addition, maintenance therapy with lenalidomide showed a significant prolongation of PFS compared with no maintenance (41.9 vs 21.6 months, p < 0.001) [42] . This study again demonstrated the significance of a deeper response and continuous maintenance therapy in younger MM patients.
Patients not eligible for autologous stem cell transplantation
Myeloma is most frequently diagnosed among people aged 65-74 years. The median age at diagnosis is reported to be 69 years with 61.9 % of patients >65 years [43] . Most elderly patients >65 years and younger patients with severe comorbidities are not eligible for HDT-ASCT; it is speculated that these patients make up approximately 70 % of newly diagnosed MM cases.
MP was the standard therapy for these patients for 40 years until the introduction of novel agents. Currently, novel agents have been demonstrated to play a crucial role in treating ASCT-ineligible patients and are widely used as front-line therapy for these patients. Although MP is not selected as the first choice for MM, it is considered for patients with a poor performance status, aged >75-80 years, or have complications interrupting the use of novel agents.
Immunomodulatory drugs (IMids)-based therapy
Clinical studies comparing melphalan, prednisone and thalidomide (MPT) versus MP in previously untreated newly diagnosed elderly patients with MM have been reported [44] [45] [46] [47] [48] [49] and a meta-analysis was performed from these six randomized controlled trials. Although the patient baseline characteristics and thalidomide regimens were different in each trial, the addition of thalidomide to MP significantly improved OS (median survival: MP 32.7 months vs MPT 39.3 months, p = 0.04) as well as PFS (median survival: MP 14.9 months vs MPT 20.3 months, p < 0.0001) and 1-year response rates [50] . Based on this evidence, MPT is considered one of the standard therapies for ASCT-ineligible patients in Europe and America; however, thalidomide is not approved for initial therapy in Japan. The main adverse effects of thalidomide are peripheral neuropathy and deep venous thrombosis.
Lenalidomide, which is a derivative of thalidomide, is also reported to be effective for ASCT-ineligible patients. A study comparing melphalan, prednisone and lenalidomide (MPR) with MP for patients not eligible for ASCT showed that MPR had a superior effect on response rate and is thought to be a promising first-line treatment for newly diagnosed elderly myeloma patients [51] . A randomized study that compared MPR followed by lenalidomide maintenance (MPR-R) with MPR or MP in patients ineligible for transplantation showed that MPR-R significantly prolonged PFS (median survival: MPR-R 31 months vs MPR 14 months, p < 0.001 or vs MP 13 months, p < 0.001) and response rates were significantly superior with MPR-R and MPR (77 and 68 %, respectively vs 50 % with MP) [52] . However, this study did not show superiority of MPR in PFS compared with MP and the PFS benefit associated with MPR-R was not noted in patients >75 years of age.
The addition of lenalidomide to dexamethasone has also investigated. Lenalidomide plus high-dose dexamethasone (RD) improved one-year PFS and overall response rate, whereas toxicities such as neutropenia and thromboembolic events despite aspirin prophylaxis were more pronounced compared with high-dose dexamethasone alone [17] . A non-inferiority trial of RD versus lenalidomide plus low-dose dexamethasone (Rd) as initial therapy including elderly patients reported that Rd is associated with better short-term OS (1 year OS: RD 87 % vs Rd 96 %, p = 0.0002) and with lower toxicity than RD [14] . Based on these results, a large-scale randomized study comparing Rd until disease progression (continuous Rd), Rd for 72 weeks (18 cycles), and MPT for 72 weeks for patients with myeloma who were ineligible for ASCT was conducted [53] . This study demonstrated that continuous Rd significantly improved PFS (median PFS: continuous Rd 25.5 months vs Rd 20.7 months and MPT 21.2 months, p < 0.001 for both comparisons) compared with 18 cycles of both Rd and MPT. In addition, continuous Rd reduced the risk of death at the interim analysis (4-year survival: continuous Rd 59 % vs MPT 51 %, p = 0.02) compared with MPT. The toxicities associated with continuous Rd (hematologic and neurologic toxic events, infections and second primary hematologic cancers) were acceptable compared with MPT. This evidence indicates that continuous Rd will become one of the standard therapies for newly diagnosed myeloma patients ineligible for ASCT.
Bortezomib-based therapy
Bortezomib, which is a proteasome inhibitor, is the only approved novel agent for initial therapy in Japan. A randomized study comparing bortezomib, melphalan and prednisone (VMP) versus MP for previously untreated HDT-ASCT-ineligible patients with symptomatic myeloma showed that VMP resulted in a significant reduction in risk of death compared with MP (median OS: VMP 56.4 months vs MP 43.1 months, p < 0.001) after a 5-year follow-up despite subsequent therapy of novel agent-based 1 3 salvage therapies [54, 55] . In addition, although OS in younger patients (<75 years) was longer than in elderly patients (≥75 years), non-statistically significant differences in OS were seen among VMP-treated patients with or without renal impairment and high-risk cytogenetics such as t (4;14), t (14;16) or del (17q). However, discontinued or reduced treatment was frequently observed in this trial because of toxicities such as peripheral neuropathy in patients who received bortezomib twice per week for 4 cycles of VMP. In this regard, the efficacy and safety of modified VMP, which reduced the infusion of bortezomib from twice per week to once per week, were investigated in order to decrease neurologic toxicities [56] . This study showed that the PFS, OS and response rate of modified VMP were similar with those of conventional VMP. In addition, the incidence of grade 3/4 peripheral neuropathy was significantly reduced in modified VMP (8 % in the once per week patients vs 28 % in the twice per week patients, p < 0.001) and the incidence of discontinued therapy because of peripheral neuropathy was also reduced in modified VMP (5 % in the once per week patients vs 15 % in the twice per week patients, p < 0.001). Similarly, the reduced intensity of bortezomib-based therapy was reported to result in effective and safe outcomes for elderly myeloma patients [57] . A subcutaneous injection of bortezomib instead of the original intravenous injection is currently recommended to reduce peripheral neuropathy without impairing efficacy in myeloma patients [58] . Based on these results, VMP is a widely used regimen in newly diagnosed patients not eligible for ASCT.
Maintenance therapy
Several maintenance therapies after initial therapy with novel agents in patients ineligible for ASCT have been investigated. Most of these studies were performed in the setting of induction therapy followed by maintenance therapies. Maintenance therapy with thalidomide after MPT, MP or cyclophosphamide, thalidomide and dexamethasone (CTD) showed a significant improvement of PFS, but the most of the studies could not confirm the prolongation of OS [44, 45, 59, 60] . Thalidomide maintenance therapy resulted in obvious neurologic toxicities and is therefore not generally recommended as standard therapy. Lenalidomide maintenance therapy after MPR also improved PFS especially in relatively younger HDT-ASCT-ineligible patients but did not show any benefit in OS [52] . Continuous Rd as described above might be an option depending on the condition of the patient [53] . A combination of bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance therapy with bortezomib and thalidomide (VT) (VMPT-VT) showed a significant improvement in PFS, response rate and OS compared with VMP without maintenance therapy. However, adverse effects such as neutropenia, cardiac events and peripheral neuropathy were more frequent in VMRT-VT patients than in VMP patients [61, 62] . VT maintenance therapy versus bortezomib plus prednisone (VP) after VMP or bortezomib, thalidomide and prednisone (VTP) as induction therapy showed a better complete response than VP but was not significantly different [57] . As described previously, the most effective drug combinations, doses or duration of maintenance therapies for patients who are not eligible for ASCT are not yet established as generally approved standard therapies. Maintenance therapies should be considered based on the condition of individual patients, i.e., age, performance status or comorbidity.
Relapsed or refractory patients for initial therapy
Despite significant improvements with novel agents, the majority of patients eventually relapse or become refractory to initial therapy due to drug resistance. Practically, salvage therapies are very important in managing these patients. However, relapsed or refractory patients represent a heterogeneous population which includes patients with relapse after stem cell transplantation, patients who are primary resistant after initial therapy or patients with relapse after initial therapy in an ASCT-ineligible setting. A number of treatment options at relapse have been reported and the appropriate therapy is selected by the disease status (e.g., short treatment-free interval from initial treatment, unfavorable cytogenetic factors, biochemical or clinical relapse), patient status (e.g., age, adverse effects of initial treatment, performance status, comorbidities, organ dysfunction), or the drug components used in initial therapy. Salvage therapies include HDT-ASCT, retreatment using previous chemotherapy regimens, and new regimens with different novel agents.
Second ASCT or retreatment with novel agents
A retrospective analysis of patients who underwent a second ASCT compared with conventional chemotherapy for relapsed MM after first ASCT showed that a second ASCT significantly improved OS and PFS; this was affected by a younger age (<55 years) at second ASCT and a longer remission duration (>18 months) from first ASCT [63] . Thus, a second ASCT in relapsed MM would be an option to consider for selected patients [64] . Although ASCT has been tried and the possibility of beneficial effects in patients with relapsed/refractory myeloma was reported, it is not sufficient to replace the established salvage therapy in the era of novel potent anti-myeloma agents [65, 66] .
Retreatment with novel agents used in initial therapy is considered in relapsed/refractory myeloma. A meta-analysis of 23 bortezomib-based retreatment studies in relapsed/ refractory myeloma reported that bortezomib retreatment is well tolerated and effective in relapsed patients [67] . The median time to progression (TTP) and OS were 7.5 and 16.6 months, respectively, and severe adverse events such as thrombocytopenia, neutropenia, and peripheral neuropathy were 35, 15 and 3 %, respectively. In addition, patients with fewer previous therapies (≤4) and relapsed (not refractory) patients achieved greater improvement in TTP and OS. Retreatment with IMids especially with lenalidomide in relapsed/refractory myeloma patients has also been investigated. Patients who received either TD or LD as initial therapy were retreated with IMiDs (thalidomide or lenalidomide) as salvage regimens [68] . The response rate for more than partial response was 44 % and lenalidomide retreatment was more effective than thalidomide retreatment. Based on this evidence, retreatment would be considered for patients who sufficiently respond to first-line novel therapy without any persisting severe adverse effects at relapse.
Salvage therapy with novel agents
Novel agents show marked progress of therapeutic strategies in relapsed/refractory myeloma in any patient situation. Clinical evidence from many investigations revealed that the first generation of novel agents (thalidomide, lenalidomide and bortezomib) were crucial in relapsed/refractory myeloma after HDT/ASCT, or after initial therapy with/without novel agents. Monotherapy with thalidomide, bortezomib or lenalidomide demonstrated a significant improvement in PFS, OS and response rate compared with dexamethasone alone in relapsed/refractory MM [66, 69, 70] . Furthermore, the addition of dexamethasone to these agents has resulted in further beneficial effects than monotherapy [69, 71, 72] . In addition, numerous studies have investigated the efficacy and safety of combinations of one or two novel agents with other cytotoxic drugs such as cyclophosphamide, pegylated liposomal doxorubicin, bendamustine, vincristine or melphalan, in relapsed/refractory myeloma [9, 10].
Next generation of novel agents
The next generation of novel agents has recently been approved in the USA and/or Europe for the treatment of patients with relapsed/refractory myeloma who have received at least two prior regimens, including bortezomib and IMids. Pomalidomide is a new IMid and in combination with low-dose dexamethasone resulted in significantly longer PFS (median: 4.0 months vs 1.9 months, p < 0.0001) and OS (median: 12.7 months vs 8.1 months, p < 0.0285), and higher response rate (response rate after median 10-month follow-up: 31 vs 10 %, p < 0.0001) compared with high-dose dexamethasone [73] . The survival advantage of pomalidomide plus dexamethasone compared to high-dose dexamethasone in PFS was observed even in patients who are refractory to both bortezomib and lenalidomide. The results of a phase 3 clinical trial comparing combination therapy of a proteasome inhibitor carfilzomib, lenalidomide and dexamethasone (KRd) with Rd in relapsed MM have been reported [74] . Patients previously treated with bortezomib or lenalidomide were included in this trial unless they were refractory to these agents. This trial demonstrated that KRd significantly extended PFS (median: 26.3 month with KRd vs 17.6 months with Rd, p = 0.0001) and increased the rate of overall response (87.1 % with KRd vs 66.7 % with Rd, p < 0.001). Furthermore, KRd is tolerable and offers superior healthrelated quality of life over 18 cycles of treatment. Finally, panobinostat, which is a potent oral pan-histone deacetylase inhibitor, was recently approved by the US Food and Drug Administration in combination with bortezomib and dexamethasone for the treatment of myeloma patients who have received at least two prior treatment regimens including bortezomib and IMids. The approval was based on the results of PFS in a subgroup of patients from a randomized phase 3 trial comparing the combination of panobinostat, bortezomib and dexamethasone with placebo, bortezomib and dexamethasone [75] . The median PFS in all patients was significantly longer in the panobinostat group than in the placebo group (12.0 months vs 8.1 months, p < 0.0001). In addition, the median PFS in the subgroup of patients who received prior treatment with bortezomib and IMids was 10.6 months in the panobinostat group and 5.8 months in the placebo group. Grade 3-4 laboratory abnormalities and adverse events such as thrombocytopenia, neutropenia, diarrhea, asthenia or fatigue, and peripheral neuropathy were reported in the panobinostat group. 
